Arcus Biosciences, Inc. (NYSE:RCUS) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Arcus Biosciences, Inc. (NYSE:RCUS) have been given an average rating of “Moderate Buy” by the eleven research firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and eight have given a buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $30.00.

RCUS has been the topic of several recent research reports. Truist Financial set a $30.00 price target on Arcus Biosciences in a research report on Friday, December 12th. Bank of America boosted their target price on shares of Arcus Biosciences from $17.00 to $26.00 and gave the stock a “neutral” rating in a research report on Friday, November 28th. Wall Street Zen lowered shares of Arcus Biosciences from a “hold” rating to a “sell” rating in a report on Saturday. Citigroup reaffirmed a “buy” rating on shares of Arcus Biosciences in a research note on Friday, December 12th. Finally, Wedbush set a $35.00 price objective on shares of Arcus Biosciences and gave the stock an “outperform” rating in a report on Wednesday, October 29th.

Arcus Biosciences Trading Up 6.6%

NYSE:RCUS opened at $22.70 on Friday. The business’s 50-day moving average is $22.68 and its two-hundred day moving average is $15.83. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.65 and a quick ratio of 3.65. Arcus Biosciences has a 12 month low of $6.50 and a 12 month high of $26.40. The firm has a market capitalization of $2.45 billion, a PE ratio of -6.60 and a beta of 0.77.

Arcus Biosciences (NYSE:RCUS) last issued its quarterly earnings data on Tuesday, October 28th. The company reported ($1.27) EPS for the quarter, topping analysts’ consensus estimates of ($1.33) by $0.06. Arcus Biosciences had a negative return on equity of 68.17% and a negative net margin of 136.40%.The company had revenue of $26.00 million for the quarter, compared to analysts’ expectations of $19.89 million. During the same quarter in the previous year, the firm posted ($1.00) earnings per share. The firm’s quarterly revenue was down 45.8% on a year-over-year basis. Research analysts predict that Arcus Biosciences will post -3.15 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Terry J. Rosen sold 28,947 shares of the stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $21.88, for a total value of $633,360.36. Following the completion of the transaction, the chief executive officer owned 2,220,553 shares of the company’s stock, valued at approximately $48,585,699.64. This represents a 1.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, President Juan C. Jaen sold 82,997 shares of the firm’s stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $24.71, for a total value of $2,050,855.87. Following the sale, the president owned 954,063 shares of the company’s stock, valued at approximately $23,574,896.73. This trade represents a 8.00% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 422,060 shares of company stock worth $9,286,202. 9.60% of the stock is currently owned by corporate insiders.

Institutional Trading of Arcus Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC raised its holdings in Arcus Biosciences by 38.8% in the fourth quarter. SG Americas Securities LLC now owns 45,488 shares of the company’s stock valued at $1,084,000 after acquiring an additional 12,714 shares in the last quarter. GAMMA Investing LLC grew its holdings in Arcus Biosciences by 17.5% during the 4th quarter. GAMMA Investing LLC now owns 3,230 shares of the company’s stock worth $77,000 after acquiring an additional 482 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Arcus Biosciences by 5.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 63,942 shares of the company’s stock valued at $870,000 after purchasing an additional 3,280 shares in the last quarter. Jacobs Levy Equity Management Inc. raised its stake in shares of Arcus Biosciences by 39.1% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,120,062 shares of the company’s stock valued at $15,233,000 after purchasing an additional 314,757 shares in the last quarter. Finally, Vestal Point Capital LP bought a new position in shares of Arcus Biosciences during the third quarter worth about $3,400,000. Institutional investors own 92.89% of the company’s stock.

Arcus Biosciences Company Profile

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.